Peer-reviewed veterinary case report
Liposome-encapsulated curcumin treatment tested for canine cancers
By Withers, Sita S et al.·Published in Veterinary and comparative oncology·2018·Department of Surgical and Radiological Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: In vitro and in vivo activity of liposome-encapsulated curcumin for naturally occurring canine cancers.
- Species:
- dog
Plain-English summary
Ten dogs with naturally occurring cancers, including osteosarcoma, melanoma, and mammary carcinoma, received a new treatment called Lipocurc, which is a special form of curcumin delivered through an IV. The goal was to see if this treatment could help control their cancer. While four out of six dogs that completed the treatment showed stable disease, meaning their cancer did not get worse, there were no noticeable changes on X-rays. This suggests that while Lipocurc may help some dogs, it might not shrink tumors significantly.
People also search for: dog cancer treatment options · curcumin for dogs with cancer · stable disease in dogs with cancer · canine osteosarcoma treatment · melanoma treatment for dogs
Abstract
Curcumin has well-established anti-cancer properties in vitro, however, its therapeutic potential has been hindered by its poor bioavailability. Lipocurc is a proprietary liposome-encapsulated curcumin formulation that enables intravenous delivery and has been shown to reach its highest concentration within lung tissue. The goal of this study was to characterize the anti-cancer and anti-angiogenic activity of Lipocurc in vitro, in addition to evaluating Lipocurc infusions in dogs with naturally occurring cancer. We therefore evaluated the effect of Lipocurc, relative to free curcumin, on the viability of canine osteosarcoma, melanoma and mammary carcinoma cell lines, as well as the ability of Lipocurc to inhibit endothelial cell viability, migration and tube formation. We also undertook a pilot clinical trial consisting of four weekly 8-hour Lipocurc infusions in 10 cancer-bearing dogs. Tumour cell proliferation was inhibited by curcumin at concentrations exceeding those achievable in the lung tissue of dogs. Similarly, equivalent high concentrations of Lipocurc and curcumin also inhibited endothelial cell viability, migration and tube formation. Four out of six dogs completing planned infusions of Lipocurc experienced stable disease; however, no radiographic responses were detected.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30088848/